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Background and purpose: Image-guided equipment for precision irradiation of small animals for pre-clin-
ical radiotherapy research became recently available. To enable downscaled radiotherapy studies that
can be translated into human radiotherapy knowledge, a treatment planning system for pre-clinical stud-
ies is required.
Material and methods: A dedicated treatment planning system (SmART-Plan) for small animal radiother-
apy studies was developed. It is based on Monte Carlo simulation of particle transport in an animal. The
voxel geometry is derived from the onboard cone beam CT imaging panel. SmART-Plan was validated
using radiochromic ﬁlm (RCF) dosimetry in various phantoms: uniform, multislab and a realistic plasti-
cized mouse geometry.
Results: Good agreement was obtained between SmART-Plan dose calculations and RCF dose measure-
ments in all phantoms. For various delivered plans agreement was obtained within 10% for the majority
of the targeted dose region, with larger differences between 10% and 20% near the penumbra regions and
for the smallest 1 mm collimator. Absolute depth and lateral dose distributions showed better agreement
for 5 and 15-mm collimators than for a 1-mm collimator, indicating that accurate dose prediction for the
smallest ﬁeld sizes is difﬁcult.
Conclusion: SmART-Plan offers a useful dose calculation tool for pre-clinical small animal irradiation
studies.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 109 (2013) 361–366
Open access under CC BY-NC-SA license. There is a limited amount of information that can be gleaned
from clinical trials with radiotherapy patients and it has been
hypothesized that greater insight can be obtained from downscal-
ing radiotherapy to the scale of small animals such as mice and rats
[1]. This is because of the rapid development of realistic preclinical
orthotropic tumor models in animals and because many radiobio-
logical experiments in the past were conducted using radiation
conditions that are not representative for the current radiotherapy
practice. Most past animal experiments used fairly large radiation
beams, did not have image-guidance and had imprecise or no
treatment planning. Hence the recent development of dedicated
image-guided precision irradiation research platforms (see [2]and references therein) and other bespoke devices based on mod-
iﬁed micro-CT devices [3] for use in preclinical studies.
The latest commercial small animal radiation research plat-
forms consist of a heavy duty X-ray machine (typically 225 kV),
precision photon beam collimators (downto 1 mm ﬁeld size), a
3D moving animal stage and an X-ray imaging panel for image-
guidance. These devices are computer-controlled and are capable
of delivering precise static or dynamic arc radiation beams to small
targets, with signiﬁcant sparing of healthy tissue compared to old-
er experiments on which our radiobiology knowledge is built.
While these devices constitute a major technological advance,
another element is needed to ensure that complex radiation dose
distributions can be delivered to small animals. A dedicated
treatment planning system (TPS) that can plan beam delivery to
arbitrarily shaped targets with complex beam arrangements is
needed to downscale human radiotherapy to the small animal
level. Current clinical TPS can usually not handle dose calculations
for kV X-rays, very small beams, and are often not equipped to deal
with multimodality images with very small voxels. Hence the need
for a TPS which may handle these aspects and can also be used for
high-throughput animal experiments for example in drug-radia-
tion synergy studies. This work describes the ongoing development
362 SmART-Plan: small animal radiotherapy planningand validation of a dedicated small animal TPS, SmART-Plan (where
SmART stands for Small Animal RadioTherapy).
There are signiﬁcant differences between treatment planning for
small animals and human patients. Chief among them is the use of
very small beams of kV X-ray photons. In the commercially avail-
able devices a broad X-ray spectrum of about 225 kV is used for
radiotherapy studies with collimators of a ﬁxed beam size of be-
tween 1 mm and several centimeters. The X-ray tube is mounted
on amovable support to enable irradiation of the specimen fromdif-
ferent sides. The sameX-ray tube, butwith a lower kV setting is used
to create a cone beamCT (CBCT) image of the specimen. The imaging
panel typically has a high resolution of about 100 lm, resulting in
3D CBCT images with a large number of voxels easily ranging in
the tens of millions, imposing demands on computer memory.
For kV photons the interaction coefﬁcients in tissues depend on
both composition and density. Therefore, whereas for radiotherapy
patient dose calculations it usually sufﬁces to consider the geome-
try to consist solely of water with a density derived from the CT
images, for kV X-ray dose calculations in the 40–225 kV photon en-
ergy range, knowledge of the X-ray spectrum and the tissue com-
position is required. Appendix A1 discusses this in more detail.
Currently, animal dose calculations use human tissue compositions
due to a lack of available data on animal tissue compositions.
Another issue related to small animal dose calculation is the use
of very small ﬁelds (1 mm–few cm). The output of an X-ray device
drops signiﬁcantly for small collimator sizes expressed as radiation
dose rate per unit X-ray tube current. This is due to a lack of scatter
equilibrium in tissue for the smallest ﬁelds but also due to obscur-
ing of the electron focal spot on the X-ray target [4].Materials and methods
Development of treatment planning platform
SmART-Plan was developed in MATLAB (v 7.11.0.584, R2010b,
TheMathWorks Inc.,Ma) and is distributedas a compiledexecutableFig. 1. Flowchart of SmART-Plan. The tasks outlined onprogram on a Linux-based platform (Ubuntu 12.04 or later). Fig. 1
shows the design of SmART-Plan. It performs absolute dose calcula-
tions on user-generated voxel phantoms from reconstructed CBCT
images by interfacing with the Monte Carlo (MC) program DOS-
XYZnrc (v 1.47 2011, NRCC, Canada). MC simulations of photon
and electron transport are performed. The dose calculations are per-
formed on a parallel computing architecture with 24 processors (12
core 2.67 GHz Intel Xeon with 24 threads total). The X-ray device
and its collimator are modeled by a photon source (i.e., phase space
ﬁles) from a previous MC simulation [5]. Currently only the most
common treatment photon spectrum is modeled (225 kVp,
0.32 mm Cu ﬁltration). SmART-Plan is validated in this paper for a
speciﬁc research platform (X-Rad 225Cx; Precision X-ray Inc., North
Branford, CT), but should be equally usable with similar systems.CT image reconstruction
CBCT scanning was performed using the research platform and
the accompanying PilotCal software (v 1.8, Precision X-ray) at
80 kVp, typical for small animal micro-CT platforms to produce a
sufﬁcient signal at the detector without excess imaging dose to the
animal [6]. 3D images (210 lm sided voxels) were reconstructed
by back projection. A Hounsﬁeld Unit (HU) to density calibration
of the CBCT scannerwas performedwith a phantomwith known tis-
sue substitute inserts (Model 467; Gammex RMI, Middleton, WI).Workﬂow of treatment planning platform
The ﬂowchart of the SmART-Plan process is shown in Fig. 1.
Dose distributions and the ﬁnal treatment plan are based on a
CBCT image acquired with the animal in the treatment position.
The CBCT image is imported in the CT upload module and can be
cropped and resized to speed up MC dose calculations. Assignment
of materials and densities is an essential part of the process not
found in a human TPS and the CT2MD (CT to Material and Density)
module is dedicated to this step. Any number of materials can bethe left are to be performed sequentially top/down.
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ties are assigned based on the HU to density calibration curve. Re-
quired material photon interaction data are read from a database
of human tissues, since the atomic composition of animal tissue
is poorly known. A voxel phantom is created that serves as input
for the MC dose calculation. Optionally, structure contours can be
created to aid treatment plan evaluation. The planning of isocen-
tres and static/dynamic beams is performed in the beam deﬁnition
module. An estimated number of histories to be simulated is calcu-
lated based on the desired statistical uncertainty. A default selec-
tion of transport parameters is provided for the user based on
previously published work of kV dose calculations [5,7] but can
be edited by the user. The dose calculation module takes care of
the complete interface with the MC dose engine and dose distribu-
tions are imported and displayed automatically. Thereafter, dose
distributions and dose volume histograms can be evaluated and
optimized by adjusting beam weights. Finally, an ini ﬁle is gener-
ated which serves as input for the PilotCal software to execute
the irradiation. See Appendix A2 for examples of screenshots of
some SmART-Plan modules.Table 1
Measured (RCF) and calculated (SmART-Plan) OF for three circular collimators and
their uncertainty.
Field size diameter
(mm)
OF (RCF) OF (SmART-
Plan)
OF correction
factor
1 0.53 ± 0.01 0.67 ± 0.02 0.79 ± 0.05
5 0.85 ± 0.02 0.86 ± 0.02 –
15 0.90 ± 0.01 0.90 ± 0.03 –
30  40 (Ref.) 1 ± 0.01 1 ± 0.02 –Validation of treatment planning platform
Absolute dose reporting in SmART-Plan was performed by
deriving a calibration factor from a comparison of a MC dose calcu-
lation in a water phantom and an absolute dose measurement
using an ionization chamber with a reference ﬁeld of 30  40 cm
at source to surface distance of 29.9 cm. By modeling the exact
geometry as used in the experiment the conversion factor from
dose per particle (MC) to dose per mAs (experiment) can be deter-
mined. This conversion factor is then valid for all simulations with
the same photon spectrum [5]. The measurements determined the
dose to the surface of the water phantom by following a medium
energy X-ray dosimetry protocol [8].
Validation of SmART-Plan was performed by examining
calculated absolute depth dose curves and dose distributions from
multiple-target irradiation plans in uniform and heterogeneous
phantoms, compared against radiochromic ﬁlm (RCF; type
Gafchromic EBT2, Ashland Specialty Ingredients, Wayne, NJ) mea-
surements for 1, 5, and 15-mm circular collimators. RCF was used
throughout this study for dose veriﬁcation due to its superior spa-
tial resolution, near water-equivalence for dosimetry, and the
avoidance of a pre-scan when using the triple-channel read out
procedure [9]. The RCF was calibrated with the research platform
for a range of doses. Films were read out (225 dpi in 48 bit, 16 bit
per color channel) 24 h after exposure with a ﬂatbed scanner Epson
PRO V750 (Seiko Epson Corporation, Japan) [9].
To validate absolute depth dose distributions for the three col-
limators, ﬁrst a CBCT image was acquired of a solid water slab
phantom. A target dose of 5 Gy was prescribed to the surface of
the phantom and MC dose calculations were launched to reach a
statistical uncertainty of less than 2%. Next, the ini ﬁle (Fig. 1)
was generated that includes the beam-on time and the target iso-
centre location that the positioning stage moves toward prior to
irradiation. Depth dose measurements for the collimators were
then performed and repeated three times by exposing ﬁve RCF
pieces on top and at different depths in the phantom. Measured
and calculated depth dose distributions were compared by taking
the average dose in a region from the maximum dose value to
80% thereof in both datasets.
More treatment plans were created for three other phantoms.
The ﬁrst two slab phantoms consisted of three RCF pieces sand-
wiched on top and between three pieces of 10-mm thick solid
water (5  8 cm2) slabs, with the second phantom differing only
by replacing the middle solid water slab by bone substitute (SB3,
Gammex-RMI, Middleton, WI). Treatment plans for these twophantoms made use of the three collimators under different irradi-
ation angles and with two target isocenter locations each targeted
with a dose of 5 Gy. Finally, a treatment plan was applied to a plas-
ticized heterogeneous mouse specimen (PlastiMouse) developed by
our anatomy department. The PlastiMouse phantom was sliced
lenghtwise to allow insertion of RCF. 3 Gy was prescribed from a
static 5-mm collimator beam targeted from above.
Results
Validation of the treatment planning system
Following the TG61 guidelines the dose rate at the surface of a
solid water phantom was found to be 0.246 Gy/min/mA. Table 1
compares measured and calculated output factors (OF) at the sur-
face; for the smallest beam an output correction factor is required.
Measured and calculated absolute dose distributions and lateral
dose proﬁles (Fig. 2) showed good agreement within 5% for the 5
and 15-mm collimator at all depths. For the smallest 1-mm colli-
mator a maximum difference of 13% at 21 mm depth was obtained.
Lateral dose proﬁles showed good agreement except in the penum-
bra regions. Dose calculation times for each collimator were: 76,
124, and 495 s for the 1, 5, and 15-mm collimator, respectively,
reﬂecting the larger number of particles required to simulate larger
beams to achieve the same statistical accuracy.
The multiple beam/multiple target treatment plan delivered in
the two slab phantom geometries achieved good agreement be-
tween the RCF measurements and the SmART-Plan dose calcula-
tions, showing maximum absolute deviations of about 2 Gy
localized near the penumbra of the beams (Fig. 3, A4). For the uni-
form solid water phantom in the regions with doses between 80%
and 100% of the maximum dose in a slice, only 1% of the voxels
exhibited a dose difference of more than 10% with respect to the
maximum dose in that slice. For the heterogeneous slab phantom
similar differences were reported except for the ﬁlm piece at 20-
mm below the surface where larger discrepancies were noted. The
primary cause for this discrepancy is amisalignment in the targeting
of the smallest beam (1 mm).When voxels with doses between 20%
and100%of themaximumdose are considered, only 4%of the voxels
showadiscrepancyexceeding10%. The total dose calculation time in
SmART-Plan for both phantoms was about 550 s. SmART-Plan
launches all the parallel dose calculations simultaneously and is
therefore only limited by the job with the longest calculation time.
Fig. 4 demonstrates that for a realistic mouse phantom (Plasti-
Mouse) the agreement between calculated and measured dose is
good,with signiﬁcantdosedifferences limited to the small beampen-
umbra region for a 5 mm collimator. For voxels with doses between
80% and 100% of the maximum dose in the slice containing the RCF,
all voxel doses were within 10% of the maximum dose in that slice.
Discussion
We demonstrated good agreement between dose calculations in
SmART-Plan and RCFmeasurements for simple beam arrangements
and for complex multiple-beam multiple-target treatment plans to
Fig. 2. Measured (RCF) and computed (MC, SmART-Plan) absolute depth dose (A) and lateral dose proﬁles, parallel to the cathode/anode direction (B). Panels (C) and (D)
display local differences (measured–calculated) dose.
Fig. 3. Comparison of calculated (top row) and RCF measured (middle row) dose distributions in a uniform solid water phantom. Also shown are the dose differences
(calculated–measured) in the bottom row. At various depths the 1, 5 and 15 mm beams can be observed.
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Fig. 4. 2D CT slices containing target location and dose distribution through the PlastiMouse phantom (top row). The bottom row shows the calculated and measured dose
distributions in the sagittal plane and their difference (calculated–measured).
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delivered plans we see agreement within 10% for the majority of
the targeted dose region, with larger differences between 10% and
20% near the penumbra regions (Figs. 3,4 and A4). Depth dose
curves and proﬁles showed better agreement for the 5 and 15-
mm collimator than the 1-mm collimator, reﬂecting the challenge
in accurately calculating and delivering a prescribed dose to a target
for beam sizes approaching the dose calculation voxel size. The out-
put correction factor for the smallest ﬁeld is caused by the inability
to accurately align the smallest collimator with the location of the
complexly shaped focal spot [4]. Dose discrepancies between
SmART-Plan and delivery can result from a number of sources:
(i) CBCT imaging (e.g., reconstruction artifacts);
(ii) MC-related dose calculation errors (e.g., poor tissue segmen-
tation or use of human tissues due to poorly known animal
tissue composition);
(iii) Machine-related delivery errors (e.g., collimator misalign-
ments, gantry sag corrections);
(iv) Measurement-related errors (e.g., absolute dosimetry, RCF);
(v) Analysis-related errors (e.g., image registration).
When CBCT is used in radiotherapy patients the conversion of
the Hounsﬁeld Units to electron densities, needed for accurate
dose calculation, may be inaccurate [10]. The conversion may be
problematic due to effects such as beam hardening and photon
scatter. However, these effects are mostly relevant for large objects
such as radiotherapy patients. For small animals photon scatter is
minimal (<5% for a 5 cm diameter water cylinder) and beam hard-
ening is insigniﬁcant. Other issues such as streaking artifacts could
lead to incorrectly assigned tissues. Therefore, more research is
needed to establish the suitability of CBCT imaging for small ani-
mal dose calculations.
Small ﬁeld dosimetry and dose calculation are known to pose
problems in radiotherapy with MV beams [11,12] and also in kV
dosimetry [13,14]. We recently studied in detail the inﬂuence of
the focal spot shape and its geometric occlusionby small collimatorsonX-ray output [4].We found it is difﬁcult to calculate absolutedose
for the smallest ﬁelds (order of a mm) but that for larger ﬁelds MC
simulationswith a detailedmodel of the irradiator offer an accuracy
of better than 5%. The level of detail in our simulations cannot im-
prove much further but the mechanical robustness and reproduc-
ibility of the irradiator can be improved upon. For dosimetry we
currently only recommend radiochromic ﬁlm due to its ease of
use, high spatial resolution and good absolute dosemeasuring capa-
bilities. We use a 3-color readout scheme [9] to avoid pre-scanning
the ﬁlm. We estimate the accuracy of radiochromic dosimetry for
the small ﬁelds to be about 5%. Others have advocated the use of so-
lid plastic dosimeters [14] but these cannot be used tomeasure dose
closer than4 mmto the surface. Regular quality assurance shouldbe
part of the operation of small animal irradiators.
In more advanced future versions of Smart-Plan we will add
multi-modality imaging planning, faster optimized dose calcula-
tions, extended DICOM import/export capabilities, advanced meth-
ods for structure contouring, dose analysis, image registration and
treatment veriﬁcation with the onboard imager [5].
Conclusion
A dedicated treatment planning system for small animal pre-
clinical work, SmART-Plan, was presented and validated. Good
agreement was achieved between measured and calculated dose
distributions in various phantoms: uniform, multislab and a realis-
tic plasticized mouse geometry. Achieving good agreement for the
smallest ﬁeld in the study (1 mm) is challenging, indicating that
pre-clinical studies with the smallest beams may require improve-
ments in the irradiation system. SmART-Plan is a useful tool to
support pre-clinical radiotherapy studies.Acknowledgments
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